Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Researchers find clues about how antibodies specialize

24.08.2004


Gene mutations are closely targeted -- enhancing the immune response while avoiding cancer

Researchers at Children’s Hospital Boston have begun unraveling the mystery of how B lymphocytes -- key infection-fighting cells in the body -- are able to create many different kinds of specialized antibodies through selective gene mutations, while being protected from random mutations that could give rise to cancers.

The findings, reported in the Aug. 26 issue of the journal Nature, will help scientists better understand two things: how the body is able to mount a strong immune defense against foreign attackers, and how cancers, particularly lymphomas, develop and might be prevented.



B lymphocytes, or B cells, are the immune-system cells responsible for producing antibodies – proteins that recognize, bind to, and neutralize viruses and other harmful pathogens. Since there is a huge diversity of pathogens in the environment – more than our genomes could possibly anticipate and encode for -- the antibody response has to be very fluid and adaptable. The human immune system handles antibody diversification through selective mutations to specific stretches of DNA in B cells that encode immunoglobulins, the proteins from which antibodies are made. Mutations in these gene segments – to the so-called variable regions -- give our B cells the ability to make unique, specialized antibodies with high affinity for a specific invader.

This mutation process, known as somatic hypermutation, is known to require an enzyme called activation-induced cytidine deaminase (AID). But how AID targets the variable region of the immunoglobulin genes -- while leaving the rest of the genetic material in the B cell untouched -- has been a mystery.

In the biochemical study reported in Nature, the Children’s Hospital Boston researchers discovered that another protein, known as replication protein A (RPA), interacts with AID, attaches to it, and directs AID to the specific segment of the B cell’s DNA required for a tailored immune response. The study details the process by which AID is biochemically modified to promote its interaction with RPA.

"Such a targeting mechanism for AID is essential for our immune system," says Dr. Frederick W. Alt, a Howard Hughes Medical Institute researcher at the Children’s Department of Molecular Medicine and senior investigator on the study. "Without it, we’d be immunodeficient, unable to diversify our antibody repertoire."

The Children’s study also has implications for the prevention of lymphomas, notes Dr. Jayanta Chaudhuri, first author on the study and a postdoctoral fellow in Alt’s laboratory.

"The AID-RPA interaction must be regulated to bring about the specificity of the mutation," Chaudhuri says. "If this regulation is impaired for some reason, then the B cell would incur a lot of random mutations and that might lead to tumors."

The next step, then, is to figure out what sometimes goes wrong and allows the AID-RPA complex to go to the wrong regions, potentially leading to activation of cancer genes. "Now that we’ve learned how AID gets access to the variable regions, we can ask how the process goes awry to cause mutations of genes that could lead to cancer," says Alt.

RPA is found throughout the body, and is known to be involved in repairing damaged DNA, but until now, it hadn’t been known to have a role in the immune system. "We’ve discovered a new function for it," says Alt. "It’s generating quite a bit of excitement in the immunology field and promises to teach us more about the immune response."

Alt has spent his career exploring the immune system’s ability to defend against a vast array of antigens through genetic rearrangements, as well as the mechanisms the body uses to suppress genomic instability, an increased tendency toward gene mutation that can lead to cancer. In recent years, these two lines of investigation--immunology and cancer -- have intersected and informed each other.

Aaron Patnode | EurekAlert!
Further information:
http://www.harvard.edu
http://www.childrenshospital.org

More articles from Life Sciences:

nachricht Researchers uncover protein-based “cancer signature”
05.12.2016 | Universität Basel

nachricht The Nagoya Protocol Creates Disadvantages for Many Countries when Applied to Microorganisms
05.12.2016 | Leibniz-Institut DSMZ-Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Shape matters when light meets atom

Mapping the interaction of a single atom with a single photon may inform design of quantum devices

Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...

Im Focus: Novel silicon etching technique crafts 3-D gradient refractive index micro-optics

A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.

Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...

Im Focus: Quantum Particles Form Droplets

In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.

“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...

Im Focus: MADMAX: Max Planck Institute for Physics takes up axion research

The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.

The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...

Im Focus: Molecules change shape when wet

Broadband rotational spectroscopy unravels structural reshaping of isolated molecules in the gas phase to accommodate water

In two recent publications in the Journal of Chemical Physics and in the Journal of Physical Chemistry Letters, researchers around Melanie Schnell from the Max...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ICTM Conference 2017: Production technology for turbomachine manufacturing of the future

16.11.2016 | Event News

Innovation Day Laser Technology – Laser Additive Manufacturing

01.11.2016 | Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

 
Latest News

IHP presents the fastest silicon-based transistor in the world

05.12.2016 | Power and Electrical Engineering

InLight study: insights into chemical processes using light

05.12.2016 | Materials Sciences

High-precision magnetic field sensing

05.12.2016 | Power and Electrical Engineering

VideoLinks
B2B-VideoLinks
More VideoLinks >>>